Business Description
Vir Biotechnology Inc
NAICS : 325412
SIC : 2834
ISIN : US92764N1028
Description
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.22 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.19 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 1.54 | |||||
| Beneish M-Score | -9.64 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -19.5 | |||||
| 3-Year EBITDA Growth Rate | -26.5 | |||||
| 3-Year EPS without NRI Growth Rate | -20.8 | |||||
| 3-Year FCF Growth Rate | -53.3 | |||||
| 3-Year Book Growth Rate | 28 | |||||
| Future 3-5Y Total Revenue Growth Rate | 15.27 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.57 | |||||
| 9-Day RSI | 40.99 | |||||
| 14-Day RSI | 37.73 | |||||
| 6-1 Month Momentum % | 22.93 | |||||
| 12-1 Month Momentum % | -59.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.05 | |||||
| Quick Ratio | 9.05 | |||||
| Cash Ratio | 8.68 | |||||
| Days Payable | 1079.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | 0.43 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 93 | |||||
| Operating Margin % | -1732.68 | |||||
| Net Margin % | -1557.35 | |||||
| FCF Margin % | -2026.53 | |||||
| ROE % | -33.7 | |||||
| ROA % | -26.34 | |||||
| ROIC % | -200.09 | |||||
| ROC (Joel Greenblatt) % | -383.74 | |||||
| ROCE % | -33.83 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 25.81 | |||||
| PB Ratio | 0.7 | |||||
| Price-to-Tangible-Book | 0.72 | |||||
| EV-to-EBIT | 0.53 | |||||
| EV-to-EBITDA | 0.54 | |||||
| EV-to-Forward-EBITDA | -0.08 | |||||
| EV-to-Revenue | -9.15 | |||||
| EV-to-Forward-Revenue | 0.36 | |||||
| EV-to-FCF | 0.45 | |||||
| Price-to-Net-Current-Asset-Value | 0.88 | |||||
| Price-to-Net-Cash | 0.93 | |||||
| Earnings Yield (Greenblatt) % | 188.68 | |||||
| FCF Yield % | -71.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VIR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vir Biotechnology Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 39.494 | ||
| EPS (TTM) ($) | -4.59 | ||
| Beta | 1.69 | ||
| Volatility % | 63.1 | ||
| 14-Day RSI | 37.73 | ||
| 14-Day ATR ($) | 0.410582 | ||
| 20-Day SMA ($) | 8.793 | ||
| 12-1 Month Momentum % | -59.22 | ||
| 52-Week Range ($) | 7.61 - 27.48 | ||
| Shares Outstanding (Mil) | 135.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vir Biotechnology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vir Biotechnology Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vir Biotechnology Inc Frequently Asked Questions
What is Vir Biotechnology Inc(VIR)'s stock price today?
The current price of VIR is $8.23. The 52 week high of VIR is $27.48 and 52 week low is $7.61.
When is next earnings date of Vir Biotechnology Inc(VIR)?
The next earnings date of Vir Biotechnology Inc(VIR) is 2024-05-02.
Does Vir Biotechnology Inc(VIR) pay dividends? If so, how much?
Vir Biotechnology Inc(VIR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers